Effects of Metformin Combined With Antifolates on HepG2 Cell Metabolism and Cellular Proliferation

Sherouk M Tawfik; Maha R A Abdollah; Mohey M Elmazar; Hassan A N El-Fawal; Anwar Abdelnaser

doi:10.3389/fonc.2022.828988

Effects of Metformin Combined With Antifolates on HepG2 Cell Metabolism and Cellular Proliferation

Front Oncol. 2022 Feb 2:12:828988. doi: 10.3389/fonc.2022.828988. eCollection 2022.

Authors

Sherouk M Tawfik^{1

2

3}, Maha R A Abdollah^{2

3}, Mohey M Elmazar², Hassan A N El-Fawal⁴, Anwar Abdelnaser⁴

Affiliations

¹ Department of Chemistry, School of Sciences and Engineering, The American University in Cairo, Cairo, Egypt.
² Department of Pharmacology and Biochemistry, Faculty of Pharmacy, The British University in Egypt (BUE), Cairo, Egypt.
³ The Center for Drug Research and Development (CDRD), Faculty of Pharmacy, The British University in Egypt (BUE), Cairo, Egypt.
⁴ Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo, Egypt.

Abstract

Hepatocellular carcinoma (HCC), one of the most prevalent types of cancers worldwide, continues to maintain high levels of resistance to standard therapy. As clinical data revealed poor response rates, the need for developing new methods has increased to improve the overall wellbeing of patients with HCC. Furthermore, a growing body of evidence shows that cancer metabolic changes are a key feature of many types of human malignancies. Metabolic reprogramming refers to cancer cells' ability to change their metabolism in order to meet the increased energy demand caused by continuous growth, rapid proliferation, and other neoplastic cell characteristics. For these reasons, metabolic pathways may become new therapeutic and chemopreventive targets. The aim of this study was to investigate the metabolic alterations associated with metformin (MET), an anti-diabetic agent when combined with two antifolate drugs: trimethoprim (TMP) or methotrexate (MTX), and how metabolic changes within the cancer cell may be used to increase cellular death. In this study, single drugs and combinations were investigated using in vitro assays including cytotoxicity assay (MTT), RT-qPCR, annexin V/PI apoptosis assay, scratch wound assay and Seahorse XF analysis, on a human HCC cell line, HepG2. The cytotoxicity assay showed that the IC₅₀ of MET as single therapy was 44.08 mM that was reduced to 22.73 mM and 29.29 mM when combined with TMP and MTX, respectively. The co-treatment of both drugs increased p53 and Bax apoptotic markers, while decreased the anti-apoptotic marker; Bcl-2. Both combinations increased the percentage of apoptotic cells and halted cancer cell migration when compared to MET alone. Furthermore, both combinations decreased the MET-induced increase in glycolysis, while also inducing mitochondrial damage, altering cancer cell bioenergetics. These findings provide an exciting insight into the anti-proliferative and apoptotic effects of MET and anti-folates on HepG2 cells, and how in combination, may potentially combat the aggressiveness of HCC.

Keywords: antifolates; glycolysis; hepatocellular carcinoma; metformin; methotrexate; oxidative phosphorylation; seahorse; trimethoprim.